EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials ( SYNCHRONIZE™ ‐1 and ‐2)

Sean Wharton iD, Carel W le Roux iD, Mikhail N Kosiborod iD, Elke Platz iD, Martina Brueckmann iD, Ania M Jastreboff iD, Samina Ajaz Hussain, Sue D Pedersen iD, Luiza Borowska, Anna Unseld, Isabel M Kloer, Lee M Kaplan iD und 1 weitere

Obesity · 2025

DOI: 10.1002/oby.24184 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Obesity, 2025. Verfasst von Sean Wharton und 12 weiteren Autor:innen. Beteiligte Einrichtung: McMaster University, Hamilton, Ontario and University of Toronto, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Clinical Trials, Phase III as Topic, Diabetes Mellitus, Type 2, Obesity, Randomized Controlled Trials as Topic. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, Boehringer Ingelheim.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

The objective of this study was to describe the rationale and design of two multinational phase 3 clinical trials of survodutide, an investigational glucagon and glucagon‐like peptide‐1 receptor dual agonist for the treatment of obesity with or without type 2 diabetes (T2D; SYNCHRONIZE‐1 and ‐2).

Methods

In these ongoing double‐blind trials, participants were randomized to once‐weekly subcutaneous injections of survodutide or placebo added to lifestyle modification. Survodutide doses are uptitrated to 3.6 or 6.0 mg, and dose flexibility is permitted.

Participants

( n = 726) in SYNCHRONIZE‐1 (NCT06066515) have a baseline BMI ≥ 30 kg/m 2 or ≥27 kg/m 2 with at least one obesity‐related complication but without T2D; participants ( n = 755) in SYNCHRONIZE‐2 (NCT06066528) have a baseline BMI ≥ 27 kg/m 2 and T2D. The primary endpoints are percentage change in body weight and proportion of participants achieving ≥5% body weight reduction from baseline to week 76. Secondary endpoints include change in systolic blood pressure and measures of glycemia. A SYNCHRONIZE‐1 substudy is evaluating changes in body composition and liver fat content using magnetic resonance imaging.

Conclusions

These trials are designed to provide robust evaluation of the efficacy, safety, and tolerability of survodutide for the treatment of obesity in the presence or absence of T2D.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Clinical Trials, Phase III as TopicDiabetes Mellitus, Type 2ObesityRandomized Controlled Trials as TopicMulticenter Studies as TopicAdultFemaleHumansMaleMiddle AgedBody Mass IndexBody WeightDouble-Blind MethodGlucagonHypoglycemic AgentsInjections, SubcutaneousTreatment OutcomeWeight LossGlucagon-Like Peptide-1 Receptor Agonists

Substanzen

GlucagonHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • McMaster University, Hamilton, Ontario and University of Toronto, Toronto, Ontario, Canada.
  • St. Vincent's University Hospital and University College Dublin School of Medicine, Dublin, Ireland.
  • Saint Luke's Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, Missouri, USA.
  • Cardiovascular Division, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
  • Boehringer Ingelheim International GmbH, Ingelheim, Germany.
  • First Department of Medicine, Faculty of Medicine Mannheim, University of Heidelberg, Mannheim, Germany.

ORCID-Profile: Sean Wharton, Carel W le Roux, Mikhail N Kosiborod, Elke Platz, Martina Brueckmann, Ania M Jastreboff, Sue D Pedersen, Lee M Kaplan

Förderung

  • NIDDK NIH HHS
  • NCATS NIH HHS
  • Boehringer Ingelheim
  • Boehringer Ingelheim Stiftung

Zitieren

APA

Wharton, S., le Roux, C. W., Kosiborod, M. N., Platz, E., Brueckmann, M., Jastreboff, A. M., Ajaz Hussain, S., Pedersen, S. D., Borowska, L., Unseld, A., Kloer, I. M., Kaplan, L. M., & SYNCHRONIZE‐1 and ‐2 trial committees and investigators (2025). Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials ( SYNCHRONIZE™ ‐1 and ‐2). Obesity. https://doi.org/10.1002/oby.24184

Vancouver

Wharton S, le Roux CW, Kosiborod MN, Platz E, Brueckmann M, Jastreboff AM, et al. Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials ( SYNCHRONIZE™ ‐1 and ‐2). Obesity. 2025. doi:10.1002/oby.24184

BibTeX
@article{Wharton2025,
  author = {Wharton, Sean and le Roux, Carel W and Kosiborod, Mikhail N and Platz, Elke and Brueckmann, Martina and Jastreboff, Ania M and Ajaz Hussain, Samina and Pedersen, Sue D and Borowska, Luiza and Unseld, Anna and Kloer, Isabel M and Kaplan, Lee M and SYNCHRONIZE‐1 and ‐2 trial committees and investigators, SYNCHRONIZE‐1 and ‐2 trial committees and investigators},
  title = {Survodutide for treatment of obesity: rationale and design of two randomized phase 3 clinical trials ( SYNCHRONIZE™ ‐1 and ‐2)},
  journal = {Obesity},
  year = {2025},
  doi = {10.1002/oby.24184}
}
Kostenlos starten →